NVIDIA
NVDA
Tesla
TSLA
Intel
INTC
Disney
DIS
Micron Technology
MU
US Stock MarketDetailed Quotes
IOBT IO Biotech
- 0.945
- -0.054-5.43%
Close Feb 28 16:00 ET
- 0.910
- -0.035-3.70%
Post 20:01 ET
62.26MMarket Cap-0.73P/E (TTM)
0.988High0.900Low135.22KVolume0.950Open0.999Pre Close125.80KTurnover0.43%Turnover RatioLossP/E (Static)65.88MShares1.85052wk High0.86P/B29.69MFloat Cap0.66052wk Low--Dividend TTM31.42MShs Float17.880Historical High--Div YieldTTM8.81%Amplitude0.660Historical Low0.930Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
IO Biotech Stock Forum
Can This New Cancer Vaccine Outsmart Tumors? IO Biotech's Breakthrough Approach
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
Sunday, 23rd February at 12:07 pm
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therape...
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
Tuesday, 4th February at 8:05 am
– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 –
NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vacci...
IO Biotech Completes Enrollment in Phase 2 Trial of Its Investigational, off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients With Resectable Melanoma or Head and Neck Cancer
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
Thursday, 9th January at 8:05 am
-- Enrollment Completed Ahead of Schedule --
-- Initial Data Expected in 2025 --
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, ...
IO Biotech Secures up to €57.5 Million in Debt Financing From the European Investment Bank
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
IO Biotech announced promising Phase 2 results for its cancer vaccine IO102-IO103 combined with KEYTRUDA® in first-line metastatic lung cancer treatment. The study showed a 55% unconfirmed/48% confirmed overall response rate and 8...
No comment yet